Angiotensin in the Arcuate: Mechanisms Integrating Cardiometabolic Control: The 2022 COH Mid-Career Award for

Samuel B R Lawton1,2, Valerie A Wagner1, Pablo Nakagawa1,3,4

  • 1Department of Physiology (S.B.R.L., V.A.W., P.N., J.L.S., C.D.S., J.L.G.), Medical College of Wisconsin, Milwaukee.

PubMed

Insights

Obesity hinders cardiovascular health. Dysfunctional control of resting metabolic rate (RMR) by angiotensin II (Ang-II) signaling in the hypothalamus prevents long-term weight loss and complicates obesity treatments.

Area of Science:

  • Neuroendocrinology
  • Cardiovascular Disease Research
  • Metabolic Regulation

Background:

  • Obesity is a major obstacle to cardiovascular disease improvement, including hypertension.
  • Long-term weight maintenance is challenging despite various weight loss interventions.
  • Defective adaptive control of resting metabolic rate (RMR) is a key factor in failed weight maintenance.

Purpose of the Study:

  • To review recent findings on the cellular and molecular control of RMR by Ang-II signaling in the hypothalamus.
  • To elucidate the neurobiological mechanisms underlying physiological and pathophysiological RMR control.
  • To explore the role of AT1R signaling in RMR adaptation and its implications for obesity and hypertension.

Main Methods:

  • Review of current research on angiotensin II (Ang-II) signaling pathways.
  • Focus on the arcuate nucleus of the hypothalamus and agouti-related peptide neurons.
  • Analysis of G protein signaling switches in Angiotensin II type 1 receptors (AT1R) and their downstream effects (β-arrestin-1/Gαi vs. Gαq).

Main Results:

  • AT1R signaling in a specific subset of hypothalamic neurons is crucial for integrative RMR control.
  • A G protein signal switch in AT1R alters cellular responses, shifting from inhibitory to stimulatory effects on RMR.
  • This qualitative change in signaling underlies RMR adaptation in obesity, potentially decreasing RMR instead of increasing it.

Conclusions:

  • The plasticity of signaling mechanisms controlling energy balance impairs obesity therapeutics.
  • Altered second-messenger coupling in AT1R signaling contributes to RMR adaptation in obesity.
  • Understanding these receptor-signaling interactions offers potential new therapeutic targets for obesity and hypertension.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396